GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

imsidolimab   Click here for help

GtoPdb Ligand ID: 14553

Synonyms: ANB-019 | ANB019
Immunopharmacology Ligand
Compound class: Antibody
Comment: Imsidolimab (ANB019) is a monoclonal antibody that targets IL1RL2, which is one of the subunits of the functional IL-36 receptor. Peptide sequences for the heavy and light chains of imsidolimab are claimed in patent WO2016168542, as components of antibody APE6155 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Imsidolimab (ANB019) was progressed as an immunomodulatory clinical candidate, primarily for the treatment of chronic, treatment-resistant inflammatory skin conditions. It was proposed to combat palmoplantar pustulosis (generalized pustular psoriasis) [2-3]. Several of the more advanced trials have been terminated.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04856930 A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa Phase 2 Interventional Vanda Pharmaceuticals
NCT04697056 A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis Phase 2 Interventional Vanda Pharmaceuticals
NCT04856917 A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris Phase 2 Interventional Vanda Pharmaceuticals
NCT05352893 Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP Phase 3 Interventional Vanda Pharmaceuticals